These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 35611697)

  • 41. Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.
    Wan H; Weng S; Sheng S; Kuang Z; Wang Q; Hu L
    Front Immunol; 2024; 15():1435127. PubMed ID: 39308870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis.
    Masucci L; Tian F; Tully S; Feng Z; McFarlane T; Chan KKW; Wong WWL
    Med Decis Making; 2024 Apr; 44(3):296-306. PubMed ID: 38486447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
    Kambhampati S; Saumoy M; Schneider Y; Serrao S; Solaimani P; Budde LE; Mei MG; Popplewell LL; Siddiqi T; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
    Blood; 2022 Nov; 140(19):2024-2036. PubMed ID: 35914220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China.
    Li N; Zheng B; Cai H; Yang T; Hong Y; Liu M; Hu J
    Support Care Cancer; 2022 Jul; 30(7):6113-6121. PubMed ID: 35419735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
    Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
    J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.
    Wang M; Jain P; Chi TL; Chen SE; Heimberger A; Weathers SP; Zheng L; Rao AV; Rossi JM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Sarkar RR; Gloude NJ; Schiff D; Murphy JD
    J Natl Cancer Inst; 2019 Jul; 111(7):719-726. PubMed ID: 30551196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
    Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
    JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
    Mian A; Hill BT
    Expert Opin Biol Ther; 2021 Apr; 21(4):435-441. PubMed ID: 33566715
    [No Abstract]   [Full Text] [Related]  

  • 53. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
    Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jiménez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Siddiqi R; Reitan J; Wade S; Salles G
    Br J Haematol; 2023 Aug; 202(4):749-759. PubMed ID: 36257914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States.
    Oluwole OO; Patel AR; Vadgama S; Smith NJ; Blissett R; Feng C; Dickinson M; Johnston PB; Perales MA
    J Med Econ; 2024; 27(1):77-83. PubMed ID: 38053517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
    McCulloch R
    Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
    Chong EA; Chong ER; Therwhanger D; Nasta SD; Landsburg DJ; Barta SK; Svoboda J; Gerson JN; Ghilardi G; Paruzzo L; Fraietta JA; Weber E; Stefano N; Porter DL; Frey NV; Garfall AL; Ruella M; Schuster SJ
    Transplant Cell Ther; 2024 Jul; 30(7):726.e1-726.e8. PubMed ID: 38494076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
    Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
    Appl Health Econ Health Policy; 2024 Sep; 22(5):749-765. PubMed ID: 38683438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
    Roth JA; Yuan Y; Othus M; Danese M; Wagner S; Penrod JR; Ramsey SD
    J Med Econ; 2021; 24(1):79-86. PubMed ID: 33334176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.